Astrazeneca ADR Aktie
72,00 €
Deine Einschätzung
Astrazeneca ADR Aktie
Was spricht für und gegen Astrazeneca ADR in den nächsten Jahren?
Pro
Kontra
Rendite von Astrazeneca ADR im Vergleich
Wertpapier | Ver.(%) | 1W | 1M | 1J | YTD | 3J | 5J |
---|---|---|---|---|---|---|---|
Astrazeneca ADR | -1,37 % | -1,37 % | -2,70 % | 15,20 % | 17,07 % | 46,94 % | - |
GSK plc ADR | 0,00 % | 0,56 % | -4,74 % | 12,42 % | 7,74 % | -13,29 % | -20,87 % |
Bayer AG ADR | -0,78 % | -0,78 % | 2,42 % | -50,39 % | -26,16 % | -49,60 % | -56,80 % |
Novo Nordisk A/S ADR | 1,68 % | -7,28 % | -9,02 % | -18,79 % | 29,00 % | 60,48 % | 185,38 % |
Kommentare
https://www.nasdaq.com/articles/is-it-too-late-to-buy-the-most-promising-pipeline-in-the-pharma-industry-2021-05-28
News
![3 No-Brainer Stocks to Buy for Under $100 Right Now: https://g.foolcdn.com/editorial/images/781193/scientists-happy.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeXpBYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--2e21eaf72b68942a8c4d434bef8c4455959fecdd/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/scientists-happy.jpg?locale=de)
3 No-Brainer Stocks to Buy for Under $100 Right Now
A low price doesn't necessarily mean low quality. That's true with lots of products and services. And it's true with stocks, too.
We asked Three Motley Fool contributors to name no-brainer
![This Pharma Stock Is Poised to Keep Outperforming the S&P 500: https://g.foolcdn.com/editorial/images/778932/pharma-researcher.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBL3VvYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--735c06001e315dd5fe7657b41c65406b53ec827b/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/pharma-researcher.jpg?locale=de)
This Pharma Stock Is Poised to Keep Outperforming the S&P 500
AstraZeneca (NASDAQ: AZN), recognized as the world's sixth-largest pharmaceutical entity by market capitalization, made a bold proclamation in May 2014. The company set an ambitious goal of
![AstraZeneca Plans to Rake in $80 Billion by 2030. Should You Buy the Stock?: https://g.foolcdn.com/editorial/images/778438/investor-holds-clipboard-and-looks-out-window.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOXFuYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--a2302664a11af76f31a6596abdc98ef66b15f382/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/investor-holds-clipboard-and-looks-out-window.jpg?locale=de)
AstraZeneca Plans to Rake in $80 Billion by 2030. Should You Buy the Stock?
AstraZeneca (NASDAQ: AZN) is embarking on a fresh business plan that will see it grow significantly between now and 2030. If it succeeds, it'll be a company that's even more prominent in the global